First-in-class subunit-selective NMDA receptor modulators to treat neuropsychiatric diseases, specifically schizophrenia and Alzheimer\'s.
There’s no risk. Start your trial today to see profiles of Mnemosyne Pharmaceuticals plus 5517 other startups.
Start Free 7 Day Trial Now
